Inspiremd reports inducement grant under nasdaq listing rule 5635(c)(4)

Tel aviv, israel and miami, may 18, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that, in connection with the appointment of shane gleason as general manager of north america and vp of global marketing in february 2023, inspiremd granted mr. gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of inspiremd's common stock. the grant of restricted stock and stock options was approved by the compensation committee of inspiremd's board of directors and was granted outside of inspiremd's 2021 equity compensation plan, with a grant date of may 17, 2023, as an inducement material to mr. gleason entering into employment with inspiremd, in accordance with nasdaq listing rule 5635(c)(4).
NSPR Ratings Summary
NSPR Quant Ranking